Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism
- PMID: 1686284
- DOI: 10.1002/jnr.490300410
Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism
Abstract
Deprenyl slows the progression of disabling symptoms in Parkinson's disease (PD) by an unknown mechanism. It can block the action of MPTP on substantia nigra compacta (SNc) neurons by inhibiting monoamine oxidase B necessary to mediate the conversion of MPTP to MPP+, its active metabolite, in astroglia. Mice were pretreated with saline or the PD-producing toxin, MPTP (30 mg/kg) daily for 5 days and then after a further 3 days (to allow for the metabolism and excretion of the MPTP) were treated with deprenyl (0.25 or 10 mg/kg) or saline 3 times weekly for 20 days. In three series of mice treated with MPTP alone or MPTP-saline, serial sections through the SNc showed that averages of 37-42% of tyrosine hydroxylase (TH) immunoreactive neurons were lost gradually over 20 days. Joint counts of the numbers of TH-immunoreactive and Nissl-stained SNc somata from immediately adjacent sections established that the reductions in the numbers of TH-immunoreactive somata at 20 days after MPTP treatment represented neuronal death. Deprenyl treatment reduced the loss of TH-immunoreactive SNc neurons to averages of 14-16% for the 10-mg/kg and 0.25-mg/kg doses, respectively, and joint Nissl/TH counts for adjacent sections showed that reduction in the loss of TH-immunoreactive soma represented the rescue of SNc neurons that would have died by 20 days. The gradual loss of SNc neurons over the 20 days following MPTP exposure may reflect the toxin's axotomy-like effects on SNc neurons or the prolonged action of sequestered MPP+.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Does melatonin help save dopaminergic cells in MPTP-treated mice?Parkinsonism Relat Disord. 2009 May;15(4):307-14. doi: 10.1016/j.parkreldis.2008.07.008. Epub 2008 Sep 14. Parkinsonism Relat Disord. 2009. PMID: 18793863
-
D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.Synapse. 2003 Oct;50(1):7-13. doi: 10.1002/syn.10239. Synapse. 2003. PMID: 12872288
-
Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.Synapse. 2001 Apr;40(1):47-54. doi: 10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S. Synapse. 2001. PMID: 11170221
-
Selegiline can mediate neuronal rescue rather than neuronal protection.Mov Disord. 1993;8 Suppl 1:S20-30. doi: 10.1002/mds.870080506. Mov Disord. 1993. PMID: 8302304 Review.
-
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review.
Cited by
-
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.J Parkinsons Dis. 2021;11(1):45-60. doi: 10.3233/JPD-201981. J Parkinsons Dis. 2021. PMID: 33074190 Free PMC article. Review.
-
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.BMC Biol. 2004 Oct 11;2:22. doi: 10.1186/1741-7007-2-22. BMC Biol. 2004. PMID: 15473914 Free PMC article.
-
High Glucose-induced Retinal Pericyte Apoptosis Depends on Association of GAPDH and Siah1.J Biol Chem. 2015 Nov 20;290(47):28311-28320. doi: 10.1074/jbc.M115.682385. Epub 2015 Oct 5. J Biol Chem. 2015. PMID: 26438826 Free PMC article.
-
MPTP mouse models of Parkinson's disease: an update.J Parkinsons Dis. 2011;1(1):19-33. doi: 10.3233/JPD-2011-11023. J Parkinsons Dis. 2011. PMID: 23275799 Free PMC article. Review.
-
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003. Clin Pharmacokinet. 2002. PMID: 11978145 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources